Clinical trial NCT01894958: A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome
Official title: A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study of NNZ-2566 in Fragile X Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Fragile X Syndrome
Keywords: Fragile X disorder
Autism
Lead sponsor: Neuren Pharmaceuticals Limited
Sponsor class: INDUSTRY
First posted: 2013-07-10
Enrollment: 72
Sex: MALE
Minimum age (years): 12
Maximum age (years): 45
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether NNZ-2566 is safe and well tolerated in the treatment of Fragile X Syndrome in adolescent and adult males.

Detailed description: Fragile X Syndrome is a genetically determined neurological disorder in which affected individuals are intellectually handicapped to varying degrees and display a variety of associated psychiatric symptoms. Clinically, Fragile X Syndrome is characterized by intellectual handicap, hyperactivity and attentional problems, autism spectrum symptoms, emotional lability and epilepsy. The epilepsy seen in Fragile X Syndrome is most commonly present in childhood, but then gradually remits towards adulthood. Physical features such as prominent ears and jaw, and hyper-extensibility of joints are frequently present but are not diagnostic. Intellectual handicap is the most common feature defining the phenotype. Treatment for the disorder is symptomatic - focusing on the management of symptoms - and supportive, requiring a multidisciplinary approach.

This study will investigate the safety and tolerability of treatment with oral administration of NNZ-2566 at 35 mg/kg or 70 mg/kg BID in adolescent or adult males with Fragile X Syndrome. The study also will also investigate measures of efficacy during treatment.

Eligibility criteria: Inclusion Criteria:

1. Fragile X Syndrome with a molecular genetic confirmation of the full FMR1 mutation.

   * Results from previously completed testing are acceptable with written documentation of the genetic results.
   * Results from PCR or Southern blot tests are acceptable
   * Results from cytogenetic testing are not acceptable but subject may be eligible if molecular genetic testing is redone.
   * A full mutation with mosaicism is allowed if:

     * Subject manifests full phenotypic profile of Fragile X syndrome
     * CGG Repeats \>200 are detected
     * Southern blot prevails over PCR, if Southern blot shows \>200 repeats and PCR results show \<200 repeats.
   * The following results would not meet criteria:

     * Deletions
     * Point mutations
     * Mosaicism without detection of \>200 CGG repeats or absence of full phenotypic profile in an individual with mosaicism
2. Males, aged 12-45 years
3. Subjects with a Clinical Global Impression - Severity (CGI-S) score of 4 or greater at Screening
4. Subjects with a total score of 30 or greater on the Aberrant Behavior Checklist (ABC) at Screening.
5. Current treatment with no more than 3 psychotropic medications. This includes medications used to treat problems with sleep onset and sleep continuity. Melatonin for difficulties with sleep onset is permissible and is excepted from the count of psychotropic medications. Similarly, anti-epileptic medications are permitted and are not denoted as "psychotropic medications" if they are used for treatment of seizures. Use of anti-epileptics for other indications such as the treatment of mood disorders counts towards the limit of permitted medications. Concurrent use of omega-3 fatty acids is also permissible and does not count towards the allowed number of concomitant psychotropic medications. A complete list of permitted concomitant psychotropic medications can be found in Appendix A.
6. Concomitant medications for chronic medical conditions are permissible. Examples of chronic medical conditions include gastroesophageal reflux disease (GERD) and asthma. Every effort should be made to keep the doses and dosing regimens of these medications stable in the 4 weeks preceding Screening and during the period between Screening and the commencement of study medication.

   1. Permitted psychotropic concomitant medications (except for anti-epileptic medications-see below) must be stable, in terms of dose and dosing regimen, for at least 4 weeks prior to Screening and must remain stable during the period between Screening and the commencement of study medication.
   2. Anti-epileptic medications must be at a stable dose and dosing regimen for 12 weeks prior to Screening and must remain stable during the period between Screening and the commencement of study medication
7. Behavioral treatments excluding psychotherapy (see exclusion criteria) must be stable for 4 weeks prior to Screening and must remain stable during the period between Screening and the commencement of study medication

   a. For each enrollee, every effort should be made to maintain stable regimens of allowed concomitant medications and allowed behavioral therapies from the time of commencement of single-blind study medication until the last study assessment.
8. Sufficient expressive language capabilities to complete the Expressive Language Sampling Task.
9. Individuals with a history of seizures should have a stable pattern of seizure activity in the 3 months preceding Screening.

Exclusion Criteria:

1. Treatment within the two weeks prior to Screening with monoamine (MAO) inhibitors, lithium, minocycline, acamprosate, racemic baclofen, investigational metabotropic glutamate receptor subtype 5 (mGluR5) medications, d-cycloserine, oxytocin, carbetocin, tricyclic antidepressants and bupropion.
2. Patients planning to commence psychotherapy, including cognitive behavior therapy (CBT), during the period of the study or those who had begun psychotherapy, including CBT, within 6 weeks prior to Screening.
3. History of, or current, cardiovascular, renal, hepatic, respiratory and/or gastrointestinal disease, which may interfere with the absorption, distribution, metabolism or excretion of the study medication, or which may interfere with the interpretation of the safety/tolerability or efficacy of the study medication.
4. History of, or current cerebrovascular disease or clinically significant brain trauma.
5. History of, or current clinically significant endocrine disorder, e.g. hypo or hyperthyroidism, or diabetes.
6. History of, or current malignancy.
7. Current major depressive disorder (patients have to be free of the most recent episode for 3 months prior to enrollment).
8. History of a DSM-5-defined substance use disorder in the 3 months prior to Screening.
9. Clinically significant abnormalities in safety laboratory tests, vital signs or ECG, as measured at Screening.
10. QT/QTcF Exclusions (any of the following):

    * QTcF \> 450 msec. Three ECGs should be obtained at the time of Screening, 5 minutes apart from each other, and the results should be averaged.
    * History of risk factors for torsade de pointes (e.g. heart failure, clinically significant hypokalemia or hypomagnesemia, or a family of long QT syndrome).
    * A serum potassium at screening \<3.0 mmol/L.
    * QT/QTcF prolongation previously or currently controlled with medication, in which normal QT/QTcF intervals could or can only be achieved with medication
    * Current treatment with other medications that have demonstrated QT/QTc prolongation and have this risk described in the Warnings and Precautions section of their Prescribing Information
11. Patients with significant hearing and/or visual impairments that may affect their ability to complete the test procedures.
12. Current treatment with insulin
13. Hgb A1C values outside of the normal reference range at Screening
14. Current or past treatment with insulin like growth factor IGF-1
15. Current or past treatment with growth hormone
16. Enrollment in another clinical trial within the 30 days preceding Screening
17. Previously randomized in this clinical trial
18. Allergy to strawberry

Primary outcomes:
measure: Adverse events
timeFrame: Through to Day 56
Secondary outcomes:
measure: Physiological changes
timeFrame: Baseline through to Day 56
measure: Behavior
timeFrame: Baseline through to Day 56
measure: Global and Functional outcome Measures
timeFrame: Baseline through to Day 56
Other outcomes:
measure: Pharmacokinetics
timeFrame: During treatment
measure: Computerized eye-tracking
timeFrame: Baseline through to Day 56
Locations:
city: Sacramento
country: United States
facility: UC Davis MIND Institute
state: California
city: Denver
country: United States
facility: Children's Hospital Colorado
state: Colorado
city: Washington
country: United States
facility: Children's National Hospital
state: District of Columbia
city: Atlanta
country: United States
facility: Emory University
state: Georgia
city: Chicago
country: United States
facility: Rush University Medical Center
state: Illinois
city: Baltimore
country: United States
facility: Kennedy Krieger Institute
state: Maryland
city: Worcester
country: United States
facility: University of Massachusetts Medical School
state: Massachusetts
city: Ann Arbor
country: United States
facility: University of Michigan
state: Michigan
city: Omaha
country: United States
facility: University of Nebraska
state: Nebraska
city: New York
country: United States
facility: Mount Sinai School of Medicine
state: New York
city: Cincinnati
country: United States
facility: Cincinnati Children's Hospital Medical Center
state: Ohio
city: Lewisburg
country: United States
facility: Autism & Developmental Medicine Institute Geisinger Health System
state: Pennsylvania
city: Media
country: United States
facility: Suburban Research Associates
state: Pennsylvania
city: Greenwood
country: United States
facility: Greenwood Genetic Center
state: South Carolina
city: Nashville
country: United States
facility: Vanderbilt University Medical Center
state: Tennessee
city: Houston
country: United States
facility: Texas Children's Hospital
state: Texas
city: Seattle
country: United States
facility: Seattle Children's Hospital
state: Washington
Study officials:
affiliation: Rush University Medical Center
name: Elizabeth M Berry-Kravis, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Emory University
name: Joseph Cubells, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Icahn School of Medicine at Mount Sinai
name: Alexander Kolevzon, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Children's Hospital Colorado
name: Nicole Tartaglia, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Massachusetts, Worcester
name: Jean Frazier, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Suburban Research Associates
name: Shivkumar Hatti, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Children's Hospital Medical Center, Cincinnati
name: Craig Erickson, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Autism & Developmental Medicine Institute Geisinger Health System
name: Thomas Challman, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Vanderbilt University Medical Center
name: Kevin Sanders, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Baylor College of Medicine
name: Diane Treadwell-Deering, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Michigan
name: Jeffrey Innis, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Nebraska
name: Howard Needleman, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Greenwood Genetic Center
name: Steve Skinner, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Seattle Children's Hospital
name: Bryan King, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: UC Davis MIND Institute
name: Randi Hagerman, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
name: Robert Findling, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Berry-Kravis E, Horrigan JP, Tartaglia N, Hagerman R, Kolevzon A, Erickson CA, Hatti S, Snape M, Yaroshinsky A, Stoms G; FXS-001 Investigators; Glass L, Jones NE. A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Fragile X Syndrome. Pediatr Neurol. 2020 Sep;110:30-41. doi: 10.1016/j.pediatrneurol.2020.04.019. Epub 2020 May 23.